PRAME immunohistochemical expression in recurrent/traumatized melanocytic nevi and the pitfall of expression by reactive fibroblasts

Emma Carraturo; Giuseppe D'Abbronzo; Giuseppe Argenziano; Gabriella Brancaccio; Camila Scharf; Elvira Moscarella; Renato Franco; Andrea Ronchi

doi:10.5826/dpc.1504a5564

PRAME immunohistochemical expression in recurrent/traumatized melanocytic nevi and the pitfall of expression by reactive fibroblasts

Authors

Emma Carraturo Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, 81100 Naples, Italy
Giuseppe D'Abbronzo Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, 81100 Naples, Italy.
Giuseppe Argenziano Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, 81100 Naples, Italy.
Gabriella Brancaccio Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, 81100 Naples, Italy
Camila Scharf Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, 81100 Naples, Italy.
Elvira Moscarella Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, 81100 Naples, Italy.
Renato Franco Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, 81100 Naples, Italy.
Andrea Ronchi Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, 81100 Naples, Italy.

Keywords:

PRAME, recurrent nevus, recurrent/traumatized melanocytic nevi

Abstract

Introduction: The recurrent/traumatized melanocytic nevus (RTMN) refers to melanocytic lesions that reappear following incomplete removal or trauma to a previous nevus, often presenting clinically and dermoscopically similar to melanoma, which complicates differential diagnosis. Histologically, RTMN exhibit melanocytic proliferation and scar tissue from prior trauma or excision. PRAME (preferentially expressed antigen in melanoma) immunohistochemistry (IHC) is emerging as a diagnostic tool for distinguishing between nevi, melanoma, and nevus-associated melanomas. However, its role in RTMN has not yet been established.

Objectives: This study aimed to evaluate the expression of PRAME in RTMN, specifically in the melanocytic and fibroblastic components, to explore its potential diagnostic utility.

Methods: A series of 22 RTMN cases from the Pathology Unit of the University of Campania Luigi Vanvitelli Hospital were reviewed. PRAME IHC was performed on formalin-fixed, paraffin-embedded tissue, and staining was evaluated in three compartments: junctional melanocytic, intradermal melanocytic, and fibroblastic scar tissue.

Results: PRAME IHC showed no positivity in the junctional or intradermal melanocytic components of any case. However, five out of 22 cases (22.7%) demonstrated PRAME positivity in the fibroblastic component, which was statistically significant (P=0.0169).

Conclusions: This study suggests that PRAME IHC is negative in the melanocytic components of RTMN, distinguishing it from melanoma. However, PRAME positivity in the fibroblastic scar component warrants careful interpretation to avoid diagnostic pitfalls. These findings emphasize the importance of considering the histological context when using PRAME as a diagnostic marker in RTMN.

References

King R, Hayzen BA, Page RN, Googe PB, Zeagler D, Mihm MC Jr. Recurrent nevus phenomenon: a clinicopathologic study of 357 cases and histologic comparison with melanoma with regression. Mod Pathol. 2009;22(5):611-617. DOI:10.1038/modpathol.2009.22.

Selim MA, Vollmer RT, Herman CM, Pham TT, Turner JW. Melanocytic nevi with nonsurgical trauma: a histopathologic study. Am J Dermatopathol. 2007;29(2):134-136. DOI:10.1097/01.dad.0000246176.81071.a6

Briatico G, Brancaccio G, Scharf C, et al. Indications for and Contraindications to Digital Monitoring of Patients with Melanocytic Lesions. Dermatol Pract Concept. 2024;14(3):e2024200. Published 2024 Jul 1. DOI:10.5826/dpc.1403a200

Blum A, Hofmann-Wellenhof R, Marghoob AA, et al. Recurrent melanocytic nevi and melanomas in dermoscopy: results of a multicenter study of the International Dermoscopy Society. JAMA Dermatol. 2014;150(2):138-145. DOI:10.1001/jamadermatol.2013.6908

Sommer LL, Barcia SM, Clarke LE, Helm KF. Persistent melanocytic nevi: a review and analysis of 205 cases. J Cutan Pathol. 2011;38(6):503-507. DOI:10.1111/j.1600-0560.2011.01692.x

Hoang MP, Prieto VG, Burchette JL, Shea CR. Recurrent melanocytic nevus: a histologic and immunohistochemical evaluation. J Cutan Pathol. 2001;28(8):400-406. DOI:10.1034/j.1600-0560.2001.028008400.x

Park HK, Leonard DD, Arrington JH 3rd, Lund HZ. Recurrent melanocytic nevi: clinical and histologic review of 175 cases. J Am Acad Dermatol. 1987;17(2 Pt 1):285-292. DOI:10.1016/s0190-9622(87)70204-7

Castagna RD, Stramari JM, Chemello RML. The recurrent nevus phenomenon. An Bras Dermatol. 2017;92(4):531-533. DOI:10.1590/abd1806-4841.20176190

Costessi A, Mahrour N, Tijchon E, et al. The tumour antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promoters. EMBO J. 2011;30(18):3786-3798. Published 2011 Aug 5. DOI:10.1038/emboj.2011.262

Umano GR, Errico ME, D'Onofrio V, et al. The Challenge of Melanocytic Lesions in Pediatric Patients: Clinical-Pathological Findings and the Diagnostic Value of PRAME. Front Oncol. 2021;11:688410. Published 2021 Jun 14. DOI:10.3389/fonc.2021.688410

Gutzmer R, Rivoltini L, Levchenko E, et al. Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. ESMO Open. 2016;1(4):e000068. Published 2016 Aug 8. DOI:10.1136/esmoopen-2016-000068

Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ. PRAME Expression in Melanocytic Tumors. Am J Surg Pathol. 2018;42(11):1456-1465. DOI:10.1097/PAS.0000000000001134

Ronchi A, Cazzato G, Ingravallo G, et al. PRAME Is an Effective Tool for the Diagnosis of Nevus-Associated Cutaneous Melanoma. Cancers (Basel). 2024;16(2):278. Published 2024 Jan 9. DOI:10.3390/cancers16020278

Wakefield C, Heffron CCBB. PRAME immunoexpression in benign fibroblasts - a diagnostic pitfall. Histopathology. 2022;80(6):1011-1013. DOI:10.1111/his.14615

Plotzke JM, Zoumberos NA, Hrycaj SM, Harms PW, Bresler SC, Chan MP. PRAME expression is similar in scar and desmoplastic melanoma. J Cutan Pathol. 2022;49(9):829-832. DOI:10.1111/cup.14286

Kunc M, Żemierowska N, Skowronek F, Biernat W. Diagnostic test accuracy meta-analysis of PRAME in distinguishing primary cutaneous melanomas from benign melanocytic lesions. Histopathology. 2023;83(1):3-14. DOI:10.1111/his.14904

Fox JC, Reed JA, Shea CR. The recurrent nevus phenomenon: a history of challenge, controversy, and discovery. Arch Pathol Lab Med. 2011;135(7):842-846. DOI:10.5858/2010-0429-RAR.1

Longo C, Moscarella E, Pepe P, et al. Confocal microscopy of recurrent naevi and recurrent melanomas: a retrospective morphological study. Br J Dermatol. 2011;165(1):61-68. DOI:10.1111/j.1365-2133.2011.10310.x

Papageorgiou V, Apalla Z, Sotiriou E, et al. The limitations of dermoscopy: false-positive and false-negative tumours. J Eur Acad Dermatol Venereol. 2018;32(6):879-888. DOI:10.1111/jdv.14782

Lezcano C, Jungbluth AA, Busam KJ. Immunohistochemistry for PRAME in Dermatopathology. Am J Dermatopathol. 2023;45(11):733-747. DOI:10.1097/DAD.0000000000002440

Lohman ME, Steen AJ, Grekin RC, North JP. The utility of PRAME staining in identifying malignant transformation of melanocytic nevi. J Cutan Pathol. 2021;48(7):856-862. DOI:10.1111/cup.13958

Ronchi A, Montella M, Zito Marino F, et al. Cytologic diagnosis of metastatic melanoma by FNA: A practical review. Cancer Cytopathol. 2022;130(1):18-29.

Kaneishi NK, Cockerell CJ. Histologic differentiation of desmoplastic melanoma from cicatrices. Am J Dermatopathol. 1998;20(2):128-34.